Motilal Oswal, however, has maintained its neutral stance. Compared to a 9 per cent Ebidta growth over FY22-24, the brokerage expects Glaxo to deliver a 19 per cent Ebidta growth over FY25-27. This ...

The state of automotive production in Canada has made more headlines over the span of just a few weeks in early 2025 than perhaps at any point since the dawn of NAFTA in the early 1990s.

GlaxoSmithKline Pharmaceuticals shares hit 20 per cent upper circuit in trade on BSE at Rs 2,421.3 per share. The buying on the counter came after the company posted its Q3 results. Around 9:52 AM, ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...